Evaluation of treatment results and access to health support of malignant pleural mesothelioma patients in Cappadocia

Aim: Malignant Pleural Mesothelioma (MPM) is frequently observed due to erionite in Cappadocia. In this study, patients who live inCappadocia region and were treated in Nevsehir State Hospital were evaluated.Material Method: In this study, the data of 22 patients admitted to Nevşehir State Hospital and diagnosed with MPM between15.7.2009-27.08.19 were evaluated retrospectively. The patients' overall survival (OS), progression-free survival (PFS) and accessto health support were examined.Results: The median follow-up period was 26 (range 1-153) months. The median age of the patients at the time of diagnosis was 65years (range 36-86). Only 2 (9.1%) patients were localized / operable at the time of diagnosis; three patients (13.6%) were metastaticand 17 (77.3%) were in-operable. The female / male ratio of our patients was 1/1. The 3 patients (13.6%) were diagnosed at NevşehirState Hospital, and 19 patients (86.4%) were diagnosed outside the Cappadocia. During the follow-up period, 19 patients (86.4%)deceased and 3 patients (13.6%) were alive. The median OS of the patients was 19 (range 1-133) months. The relapse was observedin 19 patients (86.4%). The median PFS value is 10 (range 1-126) months.Conclusion: There is not enough infrastructure in Cappadocia in terms of diagnosis and treatment of MPM. The people of Cappadocianeed to be supported in terms of access to MPM treatment. The OS of MPM has not improved significantly over the past 40 years.

PDF

___

1. Hiriart E, Deepe R, Wessels A. Mesothelium and Malignant Mesothelioma. J Dev Biol 2019;7:7.
2. Taioli E, Wolf AS, Camocho- Rivera M, et al. Determinants of Survival in Malignant Pleural Mesothelioma: A Surveillance, Epidemiology, and End Results (SEER) Study of 14,228 Patients. PloS one 2015;10:0145039.
3. Petrelli F, Ardito R, Conti B, et al. A systematic review and meta-analysis of second-line therapies for treatment of mesothelioma. Respiratory Med 2018;141:72-80.
4. Bibby AC, Tsim S, Kanellakis N, et al. Malignant pleural mesothelioma: an update on investigation, diagnosis and treatment. Eur Respir Rev 2016;25:472-86.
5. Bibby AC, Tsim S, Kanellakis N , et al. Malignant pleural mesothelioma: an update on investigation, diagnosis and treatment Eur Respir Rev 2016;25:472-86.
6. Taioli E, Wolf AS, Camacho-Rivera M, et al. Women with malignant pleural mesothelioma have a threefold better survival rate than men. Ann Thorac Surg 2014;98:1020-4.
7. Ceresoli GL, Gridelli C, Santoro A. Multidisciplinary Treatment of Malignant Pleural Mesothelioma. The Oncologist 2007;12:850-63.
8. Scherpereel A, Wallyn F, Albelda SM, Munck C. Novel therapies for malignant pleural mesothelioma. Lancet 2018;19:161-72
9. Tsao AS, Lindwasswer O, Adjei AA, et al. Current and Future Managament of Malignant Mesothelioma: A consensus Report from the National Cancer Institute Thoracic Malignancy Steering Committee,International Association for the Study of Lung Cancer and Mesothelioma Applied Research Foundation. J Thorasic Oncology 2018;13:1655-7.
10. Amin W, Linkov F, Landsittel DP. Factors influencing malignant mesothelioma survival: a retrospective review of the National Mesothelioma Virtual Bank Cohort. F1000 Res 2018;7:1184.
11. Koyuncu A, Koksal D, Ozmen O, et al. Prognostic factors in malignant pleural mesothelioma: a retrospective study of 60 Turkish patients. J Cancer Res Ther 2015; 11:216-22.
12. Kindler HL, Ismaila N, Armato SG, et al.Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Practice Guidline. J Clinical Oncology 2018; 13:1343-73.
13. Flores RM, Zakowski M, Venkatraman E, et al. Prognostic factors in the treatment of malignant pleural mesothelioma at a large tertiary referral center. J Thorac Oncol 2007;2:957-65.
14. Rusch VW, Piantadosi S, Holmes EC. The role of extrapleural pneumonectomy in malignant pleural mesothelioma. A Lung Cancer Study Group trial. J Thorac Cardiovasc Surg 1991;102:1-9.
15. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003; 21:2636-44.
16. Nowak AK. Chemotherapy for Malignant Pleural Mesothelioma: a Review of Current Management and a Look to the Future. Ann Cardiothorac Surg 2012;1:508-15.
17. Zauderer MG, Kass SL, Woo K, et al. Vinor- elbine and gemcitabine as second- or third-line therapy for malignant pleural mesothelioma. Lung Cancer 2014;84:271-4.
18. Zucali PA, Perrino M, Lorenzi E, et al. Vinor- elbine in pemetrexed-pretreated patients with ma- lignant pleural mesothelioma. Lung Cancer 2014;84:265-70.
19. Nagendran M, Pallis A, Patel K, et al. Should all patients who have mesothelioma diagnosed by videoassisted thoracoscopic surgery have their intervention sites irradiated? nteract Cardiovasc Thorac Surg 2011;13:66-9.
20. Lee C, Bayman N, Swindell R, et al. Pro- phylactic radiotherapy to intervention sites in me- sothelioma: A systematic review and survey of UK practice. Lung Cancer 2009;66:150-6.
21. Macleod N, Price A, O’Rourke N, et al. Ra- diotherapy for the treatment of pain in malignant pleural mesothelioma: A systematic review. Lung Cancer 2014;83:133-8.
22. MacLeod N, Chalmers A, O’Rourke N, et al. Is radiotherapy useful for treating pain in mesothelioma?: A phase II trial. J Thorac Oncol 2015;10:944-50.
23. MacLeod N, Kelly C, Stobo J, et al. Pain in malignant pleural mesothelioma: A prospective characterization study. Pain Med 2016;17:2119-26